跳至主要内容
临床试验/2025-522045-21-00
2025-522045-21-00招募中1 期

A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps

Boehringer Ingelheim International GmbH2 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2025年11月14日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
13
试验地点
2

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

CT Disclosure & Data Transparency

Scientific

Boehringer Ingelheim International GmbH

研究点 (2)

Loading locations...

相似试验

已完成
不适用
Investigation for advanced cancer patients' treatment preferences and their end of life careadvanced cancer
JPRN-UMIN000026436agoya City University400
招募中
不适用
A study in people with advanced cancer to test how well different doses of BI 770371 alone or in combination with ezabenlimab are tolerated
jRCT2031220031Nippon Boehringer Ingelheim Co., Ltd12
终止
1 期
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AMLAdvanced CancerSolid TumorsAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
NCT03690154Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.67
进行中(未招募)
1 期
A study for people with advanced colorectal cancer who have been treated with a specific chemotherapy regimen (Bevacizumab, Oxaliplatin, and a Fluoropyrimidine) which was ineffective in stopping the spread of the colorectal cancer. Study participants will receive a different chemotherapy regimen (Irinotecan, Folinic Acid, and 5-Fluorouracil) and be randomly and unknowingly assigned to also receive the study drug (ramucirimab) or a non-active compound (placebo).Metastatic Colorectal CancerMedDRA version: 17.0Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 100000004864
EUCTR2010-021037-32-DEEli Lilly and Company Limited, Indianapolis1,050
已完成
1 期
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the BodySolid Tumors
NCT05613036Boehringer Ingelheim13